Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ku Huang granules is a Traditional Chinese Medicine (TCM) formulation primarily utilized in China for the treatment of hepatobiliary disorders, including drug-induced liver injury (DILI), viral hepatitis, and obstructive jaundice. The formulation is composed of five herbal extracts: *Artemisiae Scopariae Herba* (Yinchen), *Gardeniae Fructus* (Zhizi), *Rhei Radix et Rhizoma* (Dahuang), *Phellodendri Chinensis Cortex* (Huangbai), and *Sophorae Flavescentis Radix* (Kushen). It exerts hepatoprotective, anti-inflammatory, and choleretic effects by modulating key signaling pathways and transporters involved in bile acid homeostasis and oxidative stress. Clinical evaluation, including a Phase 2 trial sponsored by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, has compared its efficacy to standard treatments like S-adenosylmethionine in patients with liver injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ku Huang granules.